Resveratrol and Its Analogues – Is It a New Strategy of Anticancer Therapy?

[1] Aldawsari SF, Velazquez-Martinez CA. 3,4’,5-trans-Trimethoxystilbene; a natural analogue of resveratrol with enhanced anticancer potency, The Journal of New Anticancer Agents-Springer Science + Business Media New York 2015; doi: 10.1007/s10637-015-0222-x; Published online: 28.02.2015.Search in Google Scholar

[2] Androutsopoulos VP, Ruparelia KC, Papakyriakou A, Filippakis H, TsatsakisAM, Spandidos DA. Anticancer effects of the metabolic products of the resveratrol analogue, DMU-212: structural requirements for potency, Eur. J. Med. Chem. 2011; 46 (6): 2586-95.Search in Google Scholar

[3] Belleri M, Ribatti D, Nicoli S, Cotelli F, Forti L, Vannini V, Stiva la LA, Presta M. Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4’-trimethoxystibene, Mol. Pharmcol. 2005; 67 (5): 1451-9.Search in Google Scholar

[4] Berbee JF, Wong MC, Wang Y, van der Hoorn JW, Khedoe PP, Dźwieku JB, Mol IM, Hiemstra PS, Tsikas D, Romijn JA. Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice, J.Nutr.Biochem. 2013; 24 (8): 1423-30.Search in Google Scholar

[5] Berta GN, Salamone P., Sprio AE, Di Scipio F., Marinos LM, Sapino S., Carlotti ME, Cavalli R., Di Carlo F. Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA) - induced oral carcinogenesis in hamster cheekpouch by topical application of resveratrol complexed with 2-hydroxypropyl-betacyclodextrin, Oral Oncol. 2010; 46 (1): 42-8.Search in Google Scholar

[6] Bertelli AA, Das DK. Gr apes, wines, r esver at r ol , and heart healt h, J. Cardiovasc. Pharmacol. 2009; 54: 468-476.Search in Google Scholar

[7] Cardile V, Chillemi R, Lombardo L, Sciuto S, Spatafora C, Tringali C. Antiproliferative activity of methylated analogues of E- and Z-resveratrol., Z. Naturforsch C. 2007; 62 (3-4): 189-95.10.1515/znc-2007-3-40617542483Search in Google Scholar

[8] Cardile V, Lombardo L, Spatafora C, Tringali C. Chemo-enzymatic synthesis and cell-growth inhibition activity of resveratrol analogues, Bioorganic Chemistry. 2005; 33 (1): 22-33.10.1016/j.bioorg.2004.08.00315668180Search in Google Scholar

[9] Chang TK, Yeung RK. Effect of trans-resveratrol on 7-benzyloxy-4-trifluoromethylcoumarin O-dealkylation catalyzed by human recombinant CYP3A4 and CYP3A5, Can J. Physiol. Pharmacol. 2001; 79 (3): 220-6.Search in Google Scholar

[10] Cichocki M, Baer-Dubowska W, Wierzchowski M, Murias M, Jodynis-Liebert J. 3,4,5,4’-trans-tetramethoxystilbene (DMU-212) modulates the activation of NF-ĸB, AP-1, and STAT3 transcription factors in rat liver carcinogenesis induced by initiation-promotion regimen, Mol Cell Biochem. 2014; 391 (1-2): 27-35.10.1007/s11010-014-1983-9400612724522554Search in Google Scholar

[11] Colin D, Gimazane A, Lizard G., Izard JC, Solary E, Latruffe N, Delmas D. Effects of resveratrol analogs on cell cycle progression, cell cycle associated proteins and 5-fluorouracil sensitivity in human derived colon cancer cells, Int. J. Cancer. 2009; 124 (12): 2780-8.Search in Google Scholar

[12] Cucciolla V, Borriello O, Oliva A, Galletti P, Zappia V, Ragione FD. Resveratrol:From Basic Science to the Clinic, Cell Cycle 2007; 6 (20): 2495-2510.10.4161/cc.6.20.481517726376Search in Google Scholar

[13] DEAK M, FALK H. On the chemistry of resveratrol diastereomers, Monat für Chem. 2003; 134: 883-888.10.1007/s00706-002-0554-zSearch in Google Scholar

[14] Deng YH, Alex D, Huang HQ, Wang N, Yu N, Wang YT, Leung GP, Lee SM. Inhibit ion of TNF-α- mediated endothelial cell-monocyte cell adhesion and adhesion molecules expression by the resveratrol derivative, trans-3,5,4’-trimethoxystilbene, Phytother. Res. 2011; 25 (3): 451-7.Search in Google Scholar

[15] Fulda S. Resveratrol and derivatives for the prevention and treatment of cancer, Drug Discover Today. 2010; 15 (17-18): 757-765.10.1016/j.drudis.2010.07.00520692359Search in Google Scholar

[16] Goldberg DM, Yan J, Soleas GJ. Absorption of three wine-related polyphenols in three different matrices by healthy subjects, Clin. Biochem. 2003; 36: 79-87.Search in Google Scholar

[17] Harikumar KB, Aggarwal BB. Resver atrol: a multitargeted agent for age-associated chronic diseases, Cell Cycle. 2008; 7 (8): 1020-1037.10.4161/cc.7.8.574018414053Search in Google Scholar

[18] Juan ME, Pilar Vinardell M, Planas JM. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful, Journal of Nutrition 2002; 132 (2): 257-260.10.1093/jn/132.2.25711823587Search in Google Scholar

[19] Kang SY, Lee JK, Choi O, Young Kim C, Jang JH, Hwang BY, Hong YS. Biosynthesis of methylated resveratrol analogs through the construction of an artificial biosynthetic pathway in E.coli, BMC Biotechnology, 14: 67; Published online 17.07.2014; doi:10.1186/1472-6750-14-6.Search in Google Scholar

[20] Kopeć A, Piątkowska E, Leszczyńska T, Bieżanowska-Kopeć R. Prozdrowotne właściwości resweratrolu, Nauka Technologia Jakość 2011; 5 (78): 5-15.Search in Google Scholar

[21] Kumar A, Negi G, Sharma SS. Neuroprotection by resveratrol in diabetic neuropathy: concepts & mechanisms, Curr. Med. Chem. 2013; 20 (36): 4640-5.Search in Google Scholar

[22] Lin HS, Ho PC. Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in Sprague-dawley rats: the impacts of aqeous solubility, dose escalation, food and repeated dosing on oral bioavailability, J. Pharm. Sci. 2011; 100 (10): 4491-500.Search in Google Scholar

[23] Liu Yin MY, Wy X, Zeng M, Zhao Q, Keefe Liu DL. Resveratrol protects against age-associated infertility in mice, Hum. Reprod. 2013; 28 (3): 707-717.Search in Google Scholar

[24] MA Z, MOLAVI O, HADDADI A, LAI R, GOSSAGE RA, LAVASANIFAR A. Resveratrol analog trans 3,4,5,4’-tetramethoxystilbene(DMU-212) mediates anti-tumor effects via mechanism different from that of resveratrol, Cancer Chemother. Pharmacol. 2008; 63 (1): 27-35.Search in Google Scholar

[25] Mikstacka R, Rimando AM, Dutkiewicz Z, Stefański T, Sobiak S. Design, synthesis and evaluation of the inhibitory selectivity of novel trans-resveratrol analogues on human recombinant CYP1A1, CYP1A2 and CYP1B1, Bioorganic & Medicinal Chemistry 2012; 20 (17): 7117-5126.10.1016/j.bmc.2012.07.01222863525Search in Google Scholar

[26] Okawara M, Katsuki H, Kurimoto E, Shibata H, Kume T. Akaike A. Resveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults, Biochem. Pharmacol. 2007; 73: 550-560.Search in Google Scholar

[27] Olas B. Resweratrol jako dobroczyńca w profilaktyce chorób układu krążenia, Kosmos problemy nauk biologicznych 2006; 55 (2-3): 277-285.Search in Google Scholar

[28] Ovesna Z, Horvathova-Kozics K. Structure-activity relationship of trans-resveratrol and its analogues, Neoplasma2005; 529 (6): 450-5.Search in Google Scholar

[29] Park E-J, Pezzuto JM. The pharmacology of resveratrol in animals and humans, BBA-Molecular Basis of Disease 2015; 1852 (6): 1071-1113.10.1016/j.bbadis.2015.01.01425652123Search in Google Scholar

[30] PERVAIZ S. Resveratrol: from grapevines to mammalian biology, FASEB J. 2003; 17: 1975-1985.10.1096/fj.03-0168rev14597667Search in Google Scholar

[31] Piotrowska H, Myszkowski K, Ziółkowska A, Kulcenty K, Wierzchowski M, Kaczmarek M, Murias M, Kwiatkowska-Borowczyk E, Jodynis-Liebert J. Resveratrol analogue 3,4,4’,5-tetramethoxystilbene inhibits growth, arrests cell cycle and induces apoptosis in ovarian SKOV-3 and A-2780 cancer cells, Toxicol. Apppl. Pharmacol. 2012; 263 (1): 53-60.Search in Google Scholar

[32] Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, RupareliaKC,Lamb JH, Farmer PB, Stanley LA, Burke MD. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B, Br. J. Cancer 2002; 86: 774-778.10.1038/sj.bjc.6600197237530411875742Search in Google Scholar

[33] Rahal K, Schmiedlin-Ren P, Adler J, Dhanani M, Sultani V, Rittershaus AC, Reingold L, McKenna BJ, Christman GM. Resveratrol has anti-inflammatory and antifibrotic effects in the peptidoglycan- polysaccharide rat model of Crohn’s disease, Inflamm Bowel Dis. 2012; 18 (4): 613-23.10.1002/ibd.21843343322622431488Search in Google Scholar

[34] Regev-Shoshani G, Shoseyov O, Bilkis I, Kerem Z. Glycosylation of resveratrol protects it from enzymic oxidation, Biochem.J. 2003; 374: 157-163.Search in Google Scholar

[35] Roberti M, Pizzirani D, Simoni D, Rondanin R, Baruchello R, Bonora C, Buscemi F, Grimaudo S, Tolomeo M. Synthesis and biological evaluation of resveratrol and analogs as apoptosis-inducing agents, J. Med. Chem. 2003; 46: 3546-3554.Search in Google Scholar

[36] Sale S, Tunstall RG, Ruparelia KC, Potter GA, Steward WP, Gescher AJ. Comparison of the effects of the chemopreventive agent resveratrol and its analog trans 3,4,5,4’-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells, Int. J. Cancer. 2005; 115 (2): 194-201.Search in Google Scholar

[37] Sale S, Verschoyle RD, Boocock D, Jones DJ.L, Wilsher N, Ruparelia KC, Potter GA, Farmer PB, Steward WP, Gescher AJ. Pharmacokinetics in miceand growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4’-tetramethoxystilbene, Br. J. Cancer 2004; 90 (3): 736-744.10.1038/sj.bjc.6601568240958714760392Search in Google Scholar

[38] Schrauwen P, Timmers S. Can resveratrol help to maintain metabolic helath?, Proc. Nut.r Soc. 2014; 73 (2): 271-7.Search in Google Scholar

[39] Simoni D, Roberti M, Invidiata FP, Aiello E, Aiello S, Marchett P. Stilbene-based anticancer agents: Resveratrol analogues active toward HL-60 leukemic cells with a non-specific phas mechanism., Bioorg. Med. Chem. Lett. 2006; 16 (12): 3245-3248.Search in Google Scholar

[40] Singh N, Agrawal M, Dore S. Neuroprotective properties and mechanisms of resveratrol in in vitro and in vivo experimental cerebral stroke models., ACS Chem. Neurosci. 2013; 4 (8): 1151-1162.Search in Google Scholar

[41] Sun X. Measurement and correlation of stability of trans-resveratrol in 11 solvents at T=(278,2, 288.2, 298.2 and 318.2), K. J. Chem. Thermodynamics 2008; 40: 735- 738.Search in Google Scholar

[42] Szaefer H, Cichocki M, Majchrzak-Celińska A. Nowe cytochromy P450 jako biomarkery i potencjalne cele oddziaływania w chemio prewencji i terapii nowotworów, PostepyHig. Med. Dosw. (online) 2013; 67: 709-718.Search in Google Scholar

[43] Udenigwe CC, Ramprasath VR, Aluko RE. Jones P.JH. Potential of resveratrol in anticancer and anti- -inflammatory therapy, Nutrition Reviews 2008; 66 (8): 445-454.Search in Google Scholar

[44] Waffo-Teguo P, Hawthorne ME, Cuendet M, Merillon JM, Kinghorn AD, Pezzuto JM, Mehta RG. Potential cancer - chemopreventive activities of wine stilbenoids and flavans extracted from grape (Vitisvinifera) cell cultures, Nutr. Cancer. 2001; 40: 173.Search in Google Scholar

[45] Wenezel E, Somoza V. Metabolism and bioavailability of trans-resveratrol, Mol.Nutr.Food Res. 2005; 49: 472-481.Search in Google Scholar

[46] You-QiuXue, Jin-Ming Di, Yun Luo, Ke-Jun Cheng, Xing Wei, Zhi Shi. Resveratrol oligomers for prevention and treatment of cancers, Oxid Med Cell Longev. 2014, Published online 2014 March 23.10.1155/2014/765832398885724799982Search in Google Scholar

[47] Yu C, Shin YG, Kosmeder JW, Pezzuto JM, van Breemen RB. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate, Rapid Commun. Mass Spectrom. 2003; 17 (4): 307-13.Search in Google Scholar

[48] Zdrojewicz Z, Belowska-Bień K. Resweratrol - działanie i znaczenie kliniczne, Adv. Clin. Exp. Med. 2005; 14 (5): 1051-1056.Search in Google Scholar